Comment: Compulsory licensing of patented pharmaceutical inventions: Evaluating the options

57Citations
Citations of this article
120Readers
Mendeley users who have this article in their library.
Get full text

Abstract

In this Comment, the author traces the relevant legislative history pertaining to compulsory licensing of patented pharmaceuticals from the TRIPS Agreement of 1994 to the 2003 waiver to, and later proposed amendment of, article 31, which enables poor countries to obtain needed medicines from other countries that possess manufacturing capacity. The Comment then evaluates recent, controversial uses of the relevant legislative machinery as viewed from different critical perspectives. The Comment shows how developing countries seeking access to essential medicines can collaborate in ways that would avoid undermining incentives to innovation and other social costs attributed to compulsory licensing. It ends by defending the legality of recent measures taken to promote public health in developing countries, and by reminding developed countries that unilateral retaliation against such measures is demonstratably illegal under WTO foundational law and jurisprudence. © 2009 American Society of Law, Medicine & Ethics, Inc.

Cite

CITATION STYLE

APA

Reichman, J. H. (2009). Comment: Compulsory licensing of patented pharmaceutical inventions: Evaluating the options. Journal of Law, Medicine and Ethics. Blackwell Publishing Inc. https://doi.org/10.1111/j.1748-720X.2009.00369.x

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free